According to the updated WHO classification of tumors of hematopoietic and lymphoid tissues, specific genetic abnormalities are the key defining criteria for B lymphoblastic leukemia/lymphoma (B-ALL/LBL) as well as many myeloid neoplasms. Hyperdiploidy, hypodiploidy, t(9;22)(q34; q11.2), t(v;11q23), t(12;21)(p13;q22), t(5;14)(q31;q32), and t(1;19)(q23;p13.3) are recurrent genetic abnormalities of B-ALL/LBL. These abnormalities are associated with distinctive clinical or phenotypic features, have important prognostic implications, and concurrent occurrence is very rare [1] . Recently, we treated a case of adult B-ALL with ider(9) (q10)t(9;22)(q34;q11.2) and der(19)t(1;19)(q23;p13.3). Only 10 cases of B-ALL and 5 cases of CML in the blast phase have previously been reported with ider(9)(q10)t(9;22); thus, it is a very rare variant of t(9;22) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . In a conventional cytogenetic study conducted on this patient, der(19)t(1;19) was also observed, and it appeared to be simultaneously associated with 2 types of recurrent abnormalities. However, TCF3-PBX1 translocation was not identified by FISH or reverse transcriptase PCR (RT-PCR). TCF3-PBX1 negative t(1;19) is rare and has not been previously reported in Korea. Although they are karyotypically identical, the clinical findings associated with TCF3-PBX1 negative t(1;19) 
INTRODUCTION
According to the updated WHO classification of tumors of hematopoietic and lymphoid tissues, specific genetic abnormalities are the key defining criteria for B lymphoblastic leukemia/lymphoma (B-ALL/LBL) as well as many myeloid neoplasms. Hyperdiploidy, hypodiploidy, t(9;22)(q34; q11.2), t(v;11q23), t(12;21)(p13;q22), t(5;14)(q31;q32), and t(1;19)(q23;p13.3) are recurrent genetic abnormalities of B-ALL/LBL. These abnormalities are associated with distinctive clinical or phenotypic features, have important prognostic implications, and concurrent occurrence is very rare [1] . Recently, we treated a case of adult B-ALL with ider (9) (q10)t(9;22)(q34;q11.2) and der(19)t(1;19)(q23;p13.3). Only 10 cases of B-ALL and 5 cases of CML in the blast phase have previously been reported with ider(9)(q10)t(9;22); thus, it is a very rare variant of t(9;22) [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . In a conventional cytogenetic study conducted on this patient, der(19)t(1;19) was also observed, and it appeared to be simultaneously associated with 2 types of recurrent abnormalities. However, TCF3-PBX1 translocation was not identified by FISH or reverse transcriptase PCR (RT-PCR). TCF3-PBX1 negative t(1;19) is rare and has not been previously reported in Korea. Although they are karyotypically identical, the clinical findings associated with TCF3-PBX1 negative t (1;19) In B lymphoblastic leukemia/lymphoma (B-ALL/LBL), t(9;22)(q34;q11.2) and t(1;19)(q23;p13.3) are recurrent cytogenetic abnormalities. The concurrent occurrence of both abnormalities is very rare, and only 3 cases have been previously reported. Here, we report a case of adult B-ALL with ider(9)(q10)t(9;22)(q34;q11.2) and der(19)t(1;19)(q23;p13.3). A literature review revealed that ider(9) (q10)t(9;22) is a rare variant of t(9;22) with a deletion of the short arm of chromosome 9. Fifteen cases of ider(9)(q10)t(9;22) have been reported. This abnormality is specific to precursor B-lymphoid neoplasms, such as B-ALL or B-lymphoid blast phase of CML, and is associated with disease progression or short survival. The cytogenetic abnormality t(1;19) is also specific to B-ALL. In most instances of t(1;19), TCF3 is fused to PBX1; however, a few cases have identical translocations but no TCF3-PBX1 fusion, as was observed in our patient. We describe the first case of ider(9)(q10)t(9;22) in combination with TCF3-PBX1 negative t(1;19). The patient underwent imatinib therapy in addition to intensive chemotherapy, but failed to achieve remission. (Korean J Lab Med 2010; 30:585-90) are different from those of TCF3-PBX1 positive t(1;19) [1, 15] . This is the first report of ider(9)(q10)t(9;22) in combination with TCF3-PBX1 negative t(1;19).
CASE REPORT
A 45-yr-old Korean female was admitted for the evaluation of bicytopenia found during an ophthalmologic exami- blasts, which were uniform in appearance, small in size, and had scanty cytoplasm, and inconspicuous nucleoli (Fig.   1 ). Flow cytometric analysis revealed that the blasts were positive for CD10, CD19, CD20, CD22, CD13, CD34, CD45, HLA-DR, and TdT. Spleen, liver, and lymph nodes were not palpable on physical examination. Although a cytogenetic analysis was performed using 24-hr unstimulated cultures and synchronized high-resolution cultures from the BM aspirates, few analyzable mitoses with normal karyotype were observed, and the karyotype was 46,XX [7] . However, major BCR-ABL1 rearrangement (b3a2) was detected by RT-PCR using a Seeplex Leukemia BCR/ABL kit (Seegene, Inc., Seoul, Korea) ( and immunophenotyping were similar to those at the first diagnosis. The karyotype was 46,XX,ider(9)(q10)t(9;22)(q34; q11.2),del(9)(q10),der(19)t(1;19)(q23;p13.3),der(22)t(9;22) [20] ( (22) and on both arms of ider (9) in mitotic cells (Fig. 4C) . FISH with the TCF3/PBX1 DC, DF translocation probe showed 3 red signals and 1 green signal in 145 of 200 interphase cells;
no fusion signal was observed in mitotic cells (Fig. 4D) . The patient underwent 3 cycles of intensive chemotherapy with a hyper-CVAD regimen and imatinib therapy (400-600 mg/day). However, she failed to achieve remission and de- 
DISCUSSION
The isochromosome of the long arm of derivative chromosome 9 from t(9;22) with a deletion of 9p, ider(9)(q10)t(9; 22) is very rare. Only 15 cases have been reported to date;
5 cases with CML in the blast phase and 10 cases with ALL.
All of the previously reported cases with ider(9)(q10)t (9;22) were B-ALL or lymphoid blast phase of CML, except for 1 case of CML in the blast phase and 1 case of ALL that were not described as blast lineage. Thus, it appears that this abnormality is specific to precursor B lymphoid malignancies (Table 1) , and cyclin-dependent kinase inhibitor enzymes. These genes may be involved in tumorigenesis and/or chemosensitivity [18, 19] . Conversely, genes located on the long arm of der (9) However, the clinical significance of an additional ABL-BCR1 fusion gene due to ider(9)(q10)t (9;22) is not yet clear.
In addition, deletion of the long arm of the normal chro- [2, 24] . This study is the first report of the concurrent occurrence of ider(9)(q10)t(9;22) and TCF3-PBX1 negative t(1;19). In 2 previously reported patients who relapsed, the t(1;19)-containing clones disappeared, but t(9;22) persisted. The 2 patients who received an epipodophyllotoxin developed secondary myeloid leukemia with entirely new cytogenetic findings [24] . In our case, the patient relapsed after a 9-month remission, and the disease persisted despite intensive chemotherapy and imatinib therapy. Although both the previously reported cases and our case had poor outcomes, because of the small number of cases, it is not clear whether the additional t(1;19) increased the severity of ALL with t(9;22). According to the WHO classification, t(9;22) may be associated with other genetic abnormalities, and it is generally accepted that the clinical features are governed by the presence of t(9;22) [1] . Both ider(9)(q10)t(9;22) and TCF3-PBX1 negative t(1;19) are rare cytogenetic abnormalities of B-ALL, and a larger study and more case reports are needed to determine the prognostic significance of ider(9)(q10)t(9;22) and TCF3-PBX1 negative t(1;19).
